Decreased serum allopregnanolone and progesterone levels in male patients with bipolar disorder and their effects on cognitive functions

• Published in: European archives of psychiatry and clinical neuroscience 2024-04, Vol.274 (3), p.515-524
• Main Authors: Karademir, Mihrali, Beyazyüz, Elmas, Beyazyüz, Murat, Yılmaz, Ahsen, Albayrak, Yakup
• Format: Article
• Language: English
• Subjects: Affective disorders; Bipolar disorder; Bipolar Disorder - psychology; Body mass index; Brain-Derived Neurotrophic Factor; Cognition; Cognitive ability; Humans; Male; Mania; Medicine; Medicine & Public Health; Neuropsychological Tests; Neurosciences; Original Paper; Pregnanolone; Progesterone; Psychiatry; Remission
• ISSN: 0940-1334; 1433-8491
• DOI: 10.1007/s00406-023-01607-9

The progression of bipolar disorder (BD) is characterized by recurrent episodes of depression, mania, and hypomania, thus affecting the daily functionality of individuals. Previous studies have shown that a large proportion of patients diagnosed with BD who are in clinical remission experience significant functional disorders. The present study aimed to investigate the relationships between cognitive impairment and serum progesterone, allopregnanolone and BDNF levels in male bipolar disorder patients who are in the euthymic period. Our study included 41 euthymic male patients with bipolar disorder and 40 age, sex, body mass index (BMI) and smoking-matched male healthy control subjects. Neuropsychiatric tests such as the Stroop Test TBAG Form, Auditory Verbal Digit Span Test- Form B (VADS-B) and Cancellation Test were administered to all participants, and 5–7 ml of peripheral venous blood sample was taken from all participants. Serum allopregnanolone, progesterone and BDNF levels were also measured in all participants. Serum allopregnanolone and progesterone levels were found to be lower in bipolar patients, and it was observed that the serum level of allopregnanolone decreased as the disease duration increased. The serum BDNF levels were similar between groups. The cognitive functions assessed using the Stroop, VADS-B and cancellation tests were found to be better in healthy subjects. The neurocognitive test performances of all participants were strongly positively correlated with allopregnanolone levels. The present study supports the hypothesis that allopregnanolone acts as an endogenous mood stabilizer.